### ü´Å Pulmonary Medicine: Evaluation of Incidentally Detected Pulmonary Nodules

#### ‚úÖ True Statements
1. The evaluation of a **single pulmonary nodule** requires **review of imaging history**, **estimation of the probability of malignancy**, and **discussion of management preferences** with the patient.
2. For **incidentally noted single pulmonary nodules smaller than 6 mm** in patients at **low risk for lung cancer**, **no follow-up is required**.
3. **Nodules 8 mm or smaller** have a lower probability of malignancy, are difficult to biopsy, and are not reliably characterized by **positron emission tomography (PET)**.
4. Follow-up of **small pulmonary nodules (‚â§8 mm)**, when necessary, is usually performed by **serial chest computed tomography (CT)**.
5. **Chest CT in 6 to 12 months** is appropriate for **6 to 8 mm nodules** in low- or high-risk patients, but not for **nodules <6 mm** in low-risk patients.
6. **PET/CT** is not indicated for nodules **smaller than 8 mm** because they are below the spatial resolution of **fluorodeoxyglucose PET/CT**.

#### üí¨ Extra
2. Low risk is defined by factors such as **younger age**, **no smoking history**, **no family history of lung cancer**, and **favorable nodule features** (small size, regular margins, lower lobe location).
3. PET/CT is reserved for **solid nodules with moderate or high probability of malignancy**.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #PulmonaryNodule #AmbulatoryCare #LungCancerRisk #CT #PETCT #FleischnerSociety

#### üìö Reference
Mazzone PJ, Lam L. Evaluating the patient with a pulmonary nodule: a review. *JAMA*. 2022;327:264-73. PMID: 35040882 doi:10.1001/jama.2021.24287

#### üÜî Question ID
PMMCQ24030

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Lung Tumors, Pulmonary Nodule Evaluation

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. On imaging, **pulmonary nodules** are defined as **small opacities <3 cm** surrounded by normal lung parenchyma, whereas a **focal opacity >3 cm** is considered a **lung mass** and presumed malignant until proved otherwise.
2. **Pulmonary nodules** are frequently detected **incidentally** because of the high use of **chest CT** for other indications.
3. **Lung masses (>3 cm)** should be presumed **malignant until proved otherwise**.
4. When multiple pulmonary nodules are present, **follow-up is determined by the largest lesion**.
5. A **well-demarcated, centrally or fully calcified nodule** usually represents a **previous infectious granuloma** and is considered **benign**.
6. Common infectious causes of **benign granulomatous nodules** include **endemic fungi** (e.g., histoplasmosis) and **mycobacteria** (e.g., tuberculosis, nontuberculous mycobacteria).
7. **Subsolid nodules**, including **pure ground-glass** and **part-solid nodules**, often represent **premalignant adenocarcinoma in situ** and may grow very slowly, with doubling times between **400‚Äì800 days**.
8. **Development or growth of a solid component** in a **subsolid nodule** suggests **malignancy**.
9. **Subsolid nodules** are not reliably characterized by **PET/CT**, and **nonsurgical biopsies** have limited sensitivity.
10. The **Brock model** and similar prediction calculators estimate malignancy risk based on factors such as **age, sex, smoking history, nodule size, lung location, and border morphology**.
11. **Solid nodules >8 mm** with moderate risk should be further characterized with **PET/CT**, with management based on results.
12. **Solid nodules >8 mm** with high risk should be staged with **PET/CT** followed by **definitive management** (e.g., resection, chemotherapy, radiation).

#### üè∑Ô∏è Tags
#PulmonaryNodule #PulmonaryMedicine #Granuloma #AdenocarcinomaInSitu #PETCT #BrockModel

---

#### üóæ Supplemental Tables

<!-- Table 1: Solid Nodules -->
<table>
  <caption><strong>Recommendations for Single Pulmonary Nodule Follow-Up (Fleischner Society)</strong></caption>
  <thead>
    <tr>
      <th>Nodule Size</th>
      <th>Low-Risk Patient</th>
      <th>High-Risk Patient</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><strong>&lt;6 mm</strong></td>
      <td>No follow-up</td>
      <td>Optional CT at 12 months</td>
    </tr>
    <tr>
      <td><strong>6‚Äì8 mm</strong></td>
      <td>CT at 6‚Äì12 months; consider CT at 18‚Äì24 months</td>
      <td>CT at 6‚Äì12 months and at 18‚Äì24 months</td>
    </tr>
    <tr>
      <td><strong>&gt;8 mm</strong></td>
      <td colspan="2">CT at 3 months, PET/CT, or tissue sampling</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Recommendations for Single Pulmonary Nodule Follow-Up)
1. For **incidentally detected pulmonary nodules <6 mm** in **low-risk patients**, **no follow-up** is required.
2. For **incidentally detected pulmonary nodules <6 mm** in **high-risk patients**, **optional chest CT at 12 months** may be performed.
3. For **6‚Äì8 mm pulmonary nodules** in **low-risk patients**, **chest CT at 6‚Äì12 months** is recommended, with optional **chest CT at 18‚Äì24 months**.
4. For **6‚Äì8 mm pulmonary nodules** in **high-risk patients**, **chest CT at 6‚Äì12 months** and **again at 18‚Äì24 months** is recommended.
5. For **pulmonary nodules >8 mm** in any patient, evaluation should include **chest CT at 3 months, PET/CT, or tissue sampling**.

---

<!-- Table 2: Subsolid Nodules -->
<table>
  <caption><strong>Recommendations for Solitary Subsolid Lung Nodule Follow-Up (Fleischner Society)</strong></caption>
  <thead>
    <tr>
      <th>Imaging Findings</th>
      <th>Size</th>
      <th>Recommended Follow-Up</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pure ground glass</td>
      <td>&lt;6 mm</td>
      <td>No follow-up</td>
    </tr>
    <tr>
      <td>Pure ground glass</td>
      <td>&ge;6 mm</td>
      <td>CT at 6‚Äì12 months to confirm persistence, then CT every 2 years until 5 years</td>
    </tr>
    <tr>
      <td>Part-solid nodule</td>
      <td>&lt;6 mm</td>
      <td>No follow-up</td>
    </tr>
    <tr>
      <td>Part-solid nodule</td>
      <td>&ge;6 mm</td>
      <td>CT at 3‚Äì6 months to confirm persistence; if unchanged and solid component remains &lt;6 mm, annual CT for 5 years</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Recommendations for Solitary Subsolid Lung Nodule Follow-Up)
1. **Pure ground-glass nodules <6 mm** require **no follow-up**.
2. **Pure ground-glass nodules ‚â•6 mm** require **CT at 6‚Äì12 months to confirm persistence**, followed by **CT every 2 years up to 5 years**.
3. **Part-solid nodules <6 mm** require **no follow-up**.
4. **Part-solid nodules ‚â•6 mm** require **CT at 3‚Äì6 months to confirm persistence**; if unchanged and the solid component remains **<6 mm**, **annual CT for 5 years** is recommended.

#### üè∑Ô∏è Tags
#PulmonaryNodule #GroundGlassNodule #PartSolidNodule #FleischnerSociety #PulmonaryMedicine #AmbulatoryCare

---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="Radiographic Evolution of Part-Solid Pulmonary Nodule.jpg" alt="CT images showing part-solid pulmonary nodule evolution over 6 years." />
  <figcaption>
    <strong>Radiographic Evolution of Part-Solid Pulmonary Nodule.</strong>  
    Radiographs show a part-solid, part‚Äìground-glass nodule in the left upper lobe (A); growth in the solid component at 1 year (B); an increase in the ground-glass component at 4 years (C); and further growth of the solid component at 6 years (D). This slow growth pattern is characteristic of part-solid nodules progressing from adenocarcinoma in situ to invasive adenocarcinoma.  
    Reprinted with permission from the Radiological Society of North America. MacMahon H, Naidich DP, Goo JM, et al. *Radiology*. 2017;284:228‚Äì43. PMID: 28240562
  </figcaption>
</figure>
